Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Paine

Showing results (141-150 of 175) with videos related to

Pageof 18
Sort By:
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 9, 2018
Selection of Priority Natural Products for Evaluation as Potential Precipitants of Natural Product-Drug Interactions: A NaPDI Center Recommended ApproachEmily J Johnson, Vanessa González-Peréz, Dan-Dan Tian, et al.
Clinical Pharmacology and Therapeutics|July 1, 1996
First-pass metabolism of midazolam by the human intestineM F Paine, D D Shen, K L Kunze, et al.
Clinical Pharmacology and Therapeutics|February 2, 2026
Pharmacokinetic Evaluation of a Cinnamon Product on CYP2A6 Substrate Drugs: Application of a Novel Tool Involving the Nicotine Metabolite RatioAiden-Hung P Nguyen, Deena L Hadi, Daniel A Todd, et al.
CPT: Pharmacometrics & Systems Pharmacology|March 28, 2014
Physiologically based pharmacokinetic modeling framework for quantitative prediction of an herb-drug interactionS J Brantley, B T Gufford, R Dua, et al.
Phytotherapy Research : PTR|February 15, 2021
Hepatic organic anion transporting polypeptides mediate disposition of milk thistle flavonolignans and pharmacokinetic silymarin-drug interactionsKatherine D Lynch, Michelle L Montonye, Dan-Dan Tian, et al.
Clinical Pharmacology and Therapeutics|March 16, 2023
Clinical Assessment of the Drug Interaction Potential of the Psychotropic Natural Product KratomRakshit S Tanna, James T Nguyen, Deena L Hadi, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 29, 2011
A semiphysiologically based pharmacokinetic modeling approach to predict the dose-exposure relationship of an antiparasitic prodrug/active metabolite pairGrace Zhixia Yan, Claudia N Generaux, Miyoung Yoon, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|September 4, 2012
A mouse diversity panel approach reveals the potential for clinical kidney injury due to DB289 not predicted by classical rodent modelsAlison H Harrill, Kristina D Desmet, Kristina K Wolf, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 21, 2008
The influence of CYP3A5 genotype on dexamethasone induction of CYP3A activity in African AmericansPatrick J Roberts, Kristan D Rollins, Angela D M Kashuba, et al.
Bioorganic & Medicinal Chemistry|December 25, 2012
Enhanced bioactivity of silybin B methylation productsArlene A Sy-Cordero, Tyler N Graf, Scott P Runyon, et al.
Pageof 18

Showing results (141-150 of 175) with videos related to

Sort By:
Pageof 18
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 9, 2018
Selection of Priority Natural Products for Evaluation as Potential Precipitants of Natural Product-Drug Interactions: A NaPDI Center Recommended ApproachEmily J Johnson, Vanessa González-Peréz, Dan-Dan Tian, et al.
Clinical Pharmacology and Therapeutics|July 1, 1996
First-pass metabolism of midazolam by the human intestineM F Paine, D D Shen, K L Kunze, et al.
Clinical Pharmacology and Therapeutics|February 2, 2026
Pharmacokinetic Evaluation of a Cinnamon Product on CYP2A6 Substrate Drugs: Application of a Novel Tool Involving the Nicotine Metabolite RatioAiden-Hung P Nguyen, Deena L Hadi, Daniel A Todd, et al.
CPT: Pharmacometrics & Systems Pharmacology|March 28, 2014
Physiologically based pharmacokinetic modeling framework for quantitative prediction of an herb-drug interactionS J Brantley, B T Gufford, R Dua, et al.
Phytotherapy Research : PTR|February 15, 2021
Hepatic organic anion transporting polypeptides mediate disposition of milk thistle flavonolignans and pharmacokinetic silymarin-drug interactionsKatherine D Lynch, Michelle L Montonye, Dan-Dan Tian, et al.
Clinical Pharmacology and Therapeutics|March 16, 2023
Clinical Assessment of the Drug Interaction Potential of the Psychotropic Natural Product KratomRakshit S Tanna, James T Nguyen, Deena L Hadi, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 29, 2011
A semiphysiologically based pharmacokinetic modeling approach to predict the dose-exposure relationship of an antiparasitic prodrug/active metabolite pairGrace Zhixia Yan, Claudia N Generaux, Miyoung Yoon, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|September 4, 2012
A mouse diversity panel approach reveals the potential for clinical kidney injury due to DB289 not predicted by classical rodent modelsAlison H Harrill, Kristina D Desmet, Kristina K Wolf, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 21, 2008
The influence of CYP3A5 genotype on dexamethasone induction of CYP3A activity in African AmericansPatrick J Roberts, Kristan D Rollins, Angela D M Kashuba, et al.
Bioorganic & Medicinal Chemistry|December 25, 2012
Enhanced bioactivity of silybin B methylation productsArlene A Sy-Cordero, Tyler N Graf, Scott P Runyon, et al.
Pageof 18